Radiation combined with EGFR signal inhibitors: Head and neck cancer focus

Seminars in Radiation Oncology

Volumn 16, Issue 1, 2006, Pages 38-44

  Harari, Paul M ^a   Huang, Shyhmin ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; CANERTINIB; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; MATUZUMAB; MONOCLONAL ANTIBODY; PANITUMUMAB; PELITINIB; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DRUG ACTIVITY; FOOD AND DRUG ADMINISTRATION; HEAD AND NECK CANCER; HUMAN; INTERMETHOD COMPARISON; LARYNX CANCER; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; UNITED STATES; VALIDATION PROCESS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 29244448296     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2005.08.005     Document Type: Article

References (53)

1. N. Balaban, J. Moni, M. Shannon The effect of ionizing radiation on signal transduction Antibodies to EGF receptor sensitize A431 cells to radiation Biochim Biophys Acta 1314 1996 147 156
2. M.T. Sheridan, T. O'Dwyer, C.B. Seymour Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck Radiat Oncol Invest 5 1997 180 186
3. T. Akimoto, N.R. Hunter, L. Buchmiller Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas Clin Cancer Res 5 1999 2884 2890
4. S. Huang, J.M. Bock, P.M. Harari Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck Cancer Res 59 1999 1935 1940
5. M.N. Saleh, K.P. Raisch, M.A. Stackhouse Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation Cancer Biother Radiopharm 14 1999 451 463
6. J.A. Bonner, P.M. Harari, J. Giralt Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck A phase III study of high dose radiation therapy with or without cetuximab J Clin Oncol 22 2004 489s (abstr 5507)
7. P.M. Harari Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 2004 689 708
8. J. Song, C. Chen, D. Raben Emerging role of EGFR-targeted therapies and radiation in head and neck cancer Oncology 18 2004 1757 1767
9. S. Cohen The stimulation of epidermal proliferation by a specific protein (EGF) Dev Biol 12 1965 394 407
10. S. Cohen, G. Carpenter, L. King Jr Epidermal growth factor-receptor- protein kinase interactions. Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity J Biol Chem 255 1980 4834 4842
11. H. Masui, T. Kawamoto, J.D. Sato Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies Cancer Res 44 1984 1002 1007
12. J. Mendelsohn Growth factor receptors as targets for antitumor therapy with monoclonal antibodies Prog Allergy 45 1988 147 160
13. Z. Fan, J. Baselga, H. Masui Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts Cancer Res 53 1993 4637 4642
14. J. Baselga, L. Norton, H. Masui Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies J Natl Cancer Inst 85 1993 1327 1333
15. R.K. Schmidt-Ullrich, R.B. Mikkelsen, P. Dent Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation Oncogene 15 1997 1191 1197
16. S. Huang, P.M. Harari Epidermal growth factor receptor inhibition in cancer therapy Biology, rationale and premininary clinical results Invest New Drugs 17 1999 259 269
17. C. Bianco, R. Bianco, G. Tortora Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide Clin Cancer Res 6 2000 4343 4350
18. S.-M. Huang, P.M. Harari Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis Clin Cancer Res 6 2000 2166 2174
19. L. Milas, K. Mason, N. Hunter In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody Clin Cancer Res 6 2000 701 708
20. G.S. Rao, S. Murray, S.P. Ethier Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor Int J Radiat Oncol Biol Phys 48 2000 1519 1528
21. P.M. Harari, S. Huang Modulation of molecular targets to enhance radiation Clin Cancer Res 6 2000 323 325
22. P.M. Harari, S. Huang Head and neck cancer as a clinical model for molecular targeting of therapy Combining EGFR blockade with radiation Int J Radiat Oncol Biol Phys 49 2001 427 433
23. C. Bianco, G. Tortora, R. Bianco Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 2002 3250 3258
24. S. Huang, J. Li, E.A. Armstrong Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa) Cancer Res 62 2002 4300 4306
25. K.J. Williams, B.A. Telfer, I.J. Stratford ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model Br J Cancer 86 2002 1157 1161
26. Y.H. She, F. Lee, J. Chen The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates, radiation response of human tumors in nude mice, with a marked improvement in therapeutic index Clin Cancer Res 9 2003 3773 3778
27. S. Shintani, C. Li, M. Mihara Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer Int J Cancer 107 2003 1030 1037
28. B. Solomon, J. Hagekyriakou, M.K. Trivett EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor Int J Radiat Oncol Biol Phys 55 2003 713 723
29. M.K. Nyati, D. Maheshwari, S. Hanasoge Radiosensitization by Pan ErbB inhibitor CI-1033 in vitro and in vivo Clin Cancer Res 10 2004 691 700
30. H. Zhou, Y.-S. Kim, A. Peletier Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance Int J Radiat Oncol Biol Phys 58 2004 344 352
31. P. Chinnaiyan, S. Huang, G. Vallabhaneni Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
32. S. Nasu, K.K. Ang, Z. Fan C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability Int J Radiat Oncol Biol Phys 51 2001 474 477
33. M. Krause, C. Schutze, C. Petersen Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation A study on C225 in FaDu hSCC Radiother Oncol 74 2005 109 115
34. S. Huang, J. Li, P.M. Harari Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade Mol Cancer Ther 1 2002 507 514
35. M. Baumann, M. Krause Targeting the epidermal growth factor receptor in radiotherapy Radiobiological mechanisms, preclinical and clinical results Radiother Oncol 72 2004 257 266
36. F. Robert, M.P. Ezekiel, S.A. Spencer Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer J Clin Oncol 19 2001 3234 3243
37. J.A. Bonner, P.M. Harari, J. Giralt Improved preservation of larynx with the addition of cetuximab to radiation for cancers of the larynx and hypopharynx J Clin Oncol 23 2005 508s (abstr 5533)
38. D.G. Pfister, T.B. Aliff, D.H. Kraus Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN) Preliminary evaluation of a new combined-modality paradigm Proc Am Soc Clin Oncol 22 2003 495 (abstr 1993)
39. A. Chakravarti, W. Seiferheld, H.I. Robins An update of phase I data from RTOG 0211 A phase I/II clinical study of gefitinib+ radiation for newly-diagnosed glioblastoma (GBM) patients J Clin Oncol 22 2004 1571 (abstract)
40. K.K. Ang, B.A. Berkey, X. Tu Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356
41. D.T. Chua, J.M. Nicholls, J.S. Sham Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy Int J Radiat Oncol Biol Phys 59 2004 11 20
42. S.M. Bentzen, B.M. Atasoy, F.M. Daley Epidermal growth factor receptor expression in pre-treatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a radandomized controlled trial J Clin Oncol 23 2005 5560 5567
43. K.Y. Chung, J. Shia, N.E. Kemeny Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry J Clin Oncol 23 2005 1803 1810
44. N.J. Meropol Epidermal growth factor receptor inhibitors in colorectal cancer It's time to get back on target J Clin Oncol 23 2005 1791 1793
45. P.M. Harari, L. Contreras, M.A. Pickart Modulation of proliferation kinetics in human squamous cell carcinomas of the head and neck Arch Otolaryngol Head Neck Surg 119 1993 738 742
46. D.G. Petereit, P.M. Harari, L. Contreras Combining polyamine depletion with radiation therapy for rapidly dividing head and neck tumors Strategies for improved locoregional control Int J Radiat Oncol Biol Phys 28 1994 891 898
47. T.J. Lynch, D.W. Bell, R. Sordella Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
48. J.G. Paez, P.A. Janne, J.C. Lee EGFR mutations in lung Cancer Correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
49. G. Giaccone, R.S. Herbst, C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer A phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784
50. R.S. Herbst, G. Giaccone, J.H. Schiller Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer A phase III trial - INTACT 2 J Clin Oncol 22 2004 785 794
51. R.S. Herbst, D. Prager, R. Hermann TRIBUTE - A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 22 2004 619s (abstr 7011)
52. V.A. Miller, R. Herbst, D. Prager Long survival of never smoking non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy Sub-group analysis of TRIBUTE J Clin Oncol 22 2004 631s (abstr 7061)
53. P.M. Harari, S.-M. Huang Searching for reliable epidermal growth factor receptor response predictors Commentary re M. K. Nyati et al., radiosensitization by Pan-ErbB inhibitor CI-1033 in vitro and in vivo Clin Cancer Res 10 2004 428 432 Clin Cancer Res., 10:691-700, 2004